Form 4: Recursion Pharmaceuticals CFO Executes Stock Transactions Under 10b5-1 Plan

Recursion Pharmaceuticals' Chief Financial Officer, Michael Secora, executed multiple stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, engaged in several transactions involving the company's Class A Common Stock.
• These transactions included the exercise of stock options and the subsequent sale of shares, all conducted under a pre-established 10b5-1 trading plan.
• On November 12, 2024, Mr. Secora acquired 39,375 shares at $2.22 per share and sold 15,000 shares at a weighted average price of $7.6419.
• On November 13, 2024, he again acquired 39,375 shares at $2.22 per share and sold 15,000 shares at a weighted average price of $7.6584.
• Following these transactions, Mr. Secora directly owns 1,499,631 shares of Class A Common Stock and holds options for 2,295,063 shares.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider trading activity, which is neither positive nor negative in itself. The transactions are part of a pre-arranged plan, so there is no indication of unusual activity.

Risks

• The CFO's stock sales could be perceived negatively by the market, potentially impacting the stock price.
• The reliance on a 10b5-1 trading plan suggests a predetermined strategy for stock transactions, which may not always align with the company's best interests.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the stock transactions of key executives.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice among executives at publicly traded companies to avoid accusations of insider trading.
• The reported transactions are typical for executives who receive stock options as part of their compensation package.
• Similar filings are regularly made by executives at comparable biotech companies such as BioNTech, Moderna, and Regeneron.

Stakeholder Impact

• The stock sales by the CFO could potentially influence investor sentiment, although the transactions are part of a pre-arranged plan.
• The transactions do not directly impact employees, customers, or suppliers.

Key Dates

Keywords

stock options, insider trading, Form 4, 10b5-1 plan, executive compensation, RXRX, Recursion Pharmaceuticals, Michael Secora